BDTX
Black Diamond Therapeutics, Inc.
Biotechnology · Healthcare · United States
1.78
close · 2026-10-30
value
43
cheaper than peers43
quality
54
stronger fundamentals54
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, latest year | 29.0% | 100 |
| earnings yield, latest year | 21.9% | 99 |
| price to book | 1.06× | 76 |
| earnings yield, 2 years ago | -105.6% | 34 |
| earnings yield, 1 year ago | -71.3% | 32 |
| earnings yield, 3 years ago | -141.6% | 29 |
| cash flow yield, 1 year ago | -61.1% | 20 |
| cash flow yield, 2 years ago | -65.4% | 18 |
| cash flow yield, 3 years ago | -83.6% | 15 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -37.2% | 78 |
| operating margin | 0.0% | 50 |
| debt to equity | 17.7% | 29 |
3 of 4 measures available
Facts
| market cap | $102M |
| free cash flow | -$23.6M |
| employees | 21 |
| first trade | 2020-01-31 |
| next earnings | 2026-08-05 |
| fundamentals updated | 2026-08-14 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 0.39 | -1.27 | -1.88 | -2.52 |
| free cash flow | $29.6M | -$62.3M | -$66.8M | -$85.3M |
| net income | $22.4M | -$69.7M | -$82.4M | -$91.2M |
| revenue | $70.0M | $0 | $0 | $0 |
| unusual items | -$7.3M | $0 | $0 | $2.2M |